TO:  Docket EPA-HQ-OAR-2013-0495
DATE:  July 31, 2015
RE: Consideration of Costs and Benefits Under the Clean Air Act
Economics offers a rich literature, addressing both theory and methods, relating to the consideration costs and benefits in decision making.  Notably, economics distinguishes between an efficiency test, measuring potential improvements in economic efficiency, and methods to assess changes in social welfare.  The efficiency test assesses the gains or losses in economic efficiency using a well-defined framework commonly known as benefit-cost analysis (BCA).  Economics recognizes that a change in economic efficiency (net benefits) can be a factor contributing to a change in social welfare, but does not by itself determine whether a given action makes society as a whole better or worse off.  Rather, assessing changes in social welfare requires consideration of a much greater array of economic impacts and consequences of a regulation.
Pollution, a "negative externality" in economic terms, contributes to a well-identified market failure that results in outcomes that are not economically efficient. BCA is intended to help identify what degree of regulation would address this externality, resulting in an economically efficient outcome. There is a well-developed body of economics literature identifying rigorous approaches for conducting BCA, and EPA's Guidelines for Preparing Economic Analyses and OMB's Circular A-4 follow and are consistent with this literature.   When EPA conducts a BCA, the agency is assessing, to the extent practicable given available data and methods, whether the regulation will increase or decrease economic efficiency.  This efficiency test, however, does not consider many factors that are important for decision making.
For example, BCA does not address equity or distributive justice concerns, which non-economists may refer to simply as "fairness".  In a BCA, a dollar's worth of benefits accruing to a wealthy person is counted the same as a dollar's worth of benefits accruing to one with no income.  Similarly, BCA does not weigh the costs falling on the wealthy differently than costs falling on those with low or no wealth.  Such differences in how benefits and costs of a policy change are distributed among different groups of people can be important to policy decision making. Welfare economists recognize that the effects of a policy change on equity, or distributive justice, are as important as economic efficiency in ascertaining whether that policy change is likely to improve social welfare.  Other factors that are not readily incorporated in, or that remain entirely outside, the benefit cost framework but are relevant for social welfare include:  economic and social sustainability, intergenerational effects (a special case of distributive justice), risk aversion, and uncertainty.
In addition, the performance of the benefit-cost framework in assessing even the economic efficiency dimension of social welfare can be limited due a number of theoretical and practical limitations.  These limitations include, for example, unavailability of  -  or uncertainty in  -  fundamental information about costs and benefits, heterogeneity in peoples' values and economic preferences, and important differences in susceptibility to risk.
Given the foregoing, it is not surprising that Congress in the Clean Air Act did not require benefit-cost analysis as the method for considering potential economic effects, including cost impacts, when making environmental policy and program decisions.  Instead, EPA has relied upon and implemented a number of other approaches across multiple Administrations.  For example, EPA has examined the cost-effectiveness of possible options, how costs are passed onto consumers, distributional impacts of costs, and effects of costs on the total costs and profitability of regulated entities.  Specific approaches to the consideration of costs under CAA section 111 are discussed at greater length in the preamble for this action.


[Federal Register Volume 83, Number 140 (Friday, July 20, 2018)]
[Notices]
[Pages 34653-34661]
[FR Doc No: 2018-15542]

-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Motor Carrier Safety Administration

[Docket No. FMCSA-2018-0033]

Qualification of Drivers; Exemption Applications; Diabetes
Mellitus

AGENCY: Federal Motor Carrier Safety Administration (FMCSA), DOT.

ACTION: Notice of applications for exemption; request for comments.

-----------------------------------------------------------------------

SUMMARY: FMCSA announces receipt of applications from 60 individuals
for an exemption from the prohibition in the Federal Motor Carrier
Safety Regulations (FMCSRs) against persons with insulin-treated
diabetes mellitus (ITDM) operating a commercial motor vehicle (CMV) in
interstate commerce. If granted, the exemptions would enable these
individuals with ITDM to operate CMVs in interstate commerce.

DATES: Comments must be received on or before August 20, 2018.

ADDRESSES: You may submit comments bearing the Federal Docket
Management System (FDMS) Docket No. FMCSA-2018-0033 using any of the
following methods:
     Federal eRulemaking Portal: Go to http://www.regulations.gov. Follow the online instructions for submitting
comments.
     Mail: Docket Management Facility; U.S. Department of
Transportation, 1200 New Jersey Avenue SE, West Building Ground Floor,
Room W12-140, Washington, DC 20590-0001.
     Hand Delivery: West Building Ground Floor, Room W12-140,
1200 New Jersey Avenue SE, Washington, DC, between 9 a.m. and 5 p.m.,
e.t., Monday through Friday, except Federal Holidays.
     Fax: 1-202-493-2251.
    Instructions: Each submission must include the Agency name and the
docket number(s) for this notice. Note that all comments received will
be posted without change to http://www.regulations.gov, including any
personal information provided. Please see the Privacy Act heading below
for further information.
    Docket: For access to the docket to read background documents or
comments, go to http://www.regulations.gov at any time or Room W12-140
on the ground level of the West Building, 1200 New Jersey Avenue SE,
Washington, DC, between 9 a.m. and 5 p.m., e.t., Monday through Friday,
except Federal holidays. The FDMS is available 24 hours each day e.t.,
365 days each year. If you want acknowledgment that we received your
comments, please include a self-addressed, stamped envelope or postcard
or print the acknowledgement page that appears after submitting
comments online.
    Privacy Act: In accordance with 5 U.S.C. 553(c), DOT solicits
comments from the public to better inform its rulemaking process. DOT
posts these comments, without edit, including any personal information
the commenter provides, to http://www.regulations.gov, as described in
the system of records notice (DOT/ALL-14 FDMS), which can be reviewed
at http://www.dot.gov/privacy.

FOR FURTHER INFORMATION CONTACT: Ms. Christine A. Hydock, Chief,
Medical Programs Division,<PHONE_NUMBER>, [email protected], FMCSA,
Department of Transportation, 1200 New Jersey Avenue SE, Room W64-224,
Washington, DC 20590-0001. Office hours are 8:30 a.m. to 5 p.m., e.t.,
Monday through Friday, except Federal holidays. If you have questions
regarding viewing or submitting material to the docket, contact Docket
Services, telephone<PHONE_NUMBER>.

SUPPLEMENTARY INFORMATION:

I. Background

    Under 49 U.S.C. 31136(e) and 31315, FMCSA may grant an exemption
from the FMCSRs for a five-year period if it finds ``such exemption
would likely achieve a level of safety that is equivalent to or greater
than the level that would be achieved absent such exemption.'' The
statute also allows the Agency to renew exemptions at the end of the
five-year period. FMCSA grants exemptions from the FMCSRs for a two-
year period to align with the maximum duration of a driver's medical
certification.
    The 60 individuals listed in this notice have requested an
exemption from the diabetes prohibition in 49 CFR

391.41(b)(3). Accordingly, the Agency will evaluate the qualifications
of each applicant to determine whether granting the exemption will
achieve the required level of safety mandated by statute.
    The physical qualification standard for drivers regarding diabetes
found in 49 CFR 391.41(b)(3) states that a person is physically
qualified to drive a CMV if that person has no established medical
history or clinical diagnosis of diabetes mellitus currently requiring
insulin for control. The Agency established the current requirement for
diabetes in 1970 because several risk studies indicated that drivers
with diabetes had a higher rate of crash involvement than the general
population.
    FMCSA established its diabetes exemption program, based on the
Agency's July 2000 study entitled ``A Report to Congress on the
Feasibility of a Program to Qualify Individuals with Insulin-Treated
Diabetes Mellitus to Operate in Interstate Commerce as Directed by the
Transportation Act for the 21st Century.'' The report concluded that a
safe and practicable protocol to allow some drivers with ITDM to
operate CMVs is feasible. The September 3, 2003 (68 FR 52441), Federal
Register notice in conjunction with the November 8, 2005 (70 FR 67777),
Federal Register notice provides the current protocol for allowing such
drivers to operate CMVs in interstate commerce.
    FMCSA notes that section 4129 of the Safe, Accountable, Flexible
and Efficient Transportation Equity Act: A Legacy for Users requires
the Secretary to revise its diabetes exemption program established on
September 3, 2003 (68 FR 52441). The revision must provide for
individual assessment of drivers with diabetes mellitus, and be
consistent with the criteria described in section 4018 of the
Transportation Equity Act for the 21st Century (49 U.S.C. 31305).
Section 4129 requires: (1) Elimination of the requirement for three
years of experience operating CMVs while being treated with insulin;
and (2) establishment of a specified minimum period of insulin use to
demonstrate stable control of diabetes before being allowed to operate
a CMV.
    In response to section 4129, FMCSA made immediate revisions to the
diabetes exemption program established by the September 3, 2003 notice.
FMCSA discontinued use of the three-year driving experience and
fulfilled the requirements of section 4129 while continuing to ensure
that operation of CMVs by drivers with ITDM will achieve the requisite
level of safety required of all exemptions granted under 49 U.S.C.
31136 (e). Section 4129(d) also directed FMCSA to ensure that drivers
of CMVs with ITDM are not held to a higher standard than other drivers,
with the exception of limited operating, monitoring and medical
requirements that are deemed medically necessary. The FMCSA concluded
that all of the operating, monitoring and medical requirements set out
in the September 3, 2003, notice, except as modified, were in
compliance with section 4129(d). Therefore, all of the requirements set
out in the September 3, 2003, notice, except as modified by the notice
in the Federal Register on November 8, 2005 (70 FR 67777), remain in
effect.

II. Qualifications of Applicants

Michael R. Allen

    Mr. Allen, 66, has had ITDM since 2018. His endocrinologist
examined him in 2018 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. His endocrinologist certifies that Mr. Allen understands
diabetes management and monitoring, has stable control of his diabetes
using insulin, and is able to drive a CMV safely. Mr. Allen meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2018 and certified that he has stable
nonproliferative diabetic retinopathy. He holds a Class A CDL from
Illinois.

Kenneth A. Bauer II

    Mr. Bauer, 55, has had ITDM since 2012. His endocrinologist
examined him in 2018 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. His endocrinologist certifies that Mr. Bauer understands
diabetes management and monitoring, has stable control of his diabetes
using insulin, and is able to drive a CMV safely. Mr. Bauer meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2018 and certified that he does not have
diabetic retinopathy. He holds a Class A CDL from Michigan.

Teresia K. Beaty

    Ms. Beaty, 60, has had ITDM since 2017. Her endocrinologist
examined her in 2018 and certified that she has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. Her endocrinologist certifies that Ms. Beaty understands
diabetes management and monitoring, has stable control of her diabetes
using insulin, and is able to drive a CMV safely. Ms. Beaty meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). Her
optometrist examined her in 2018 and certified that she does not have
diabetic retinopathy. She holds an operator's license from Indiana.

Mycah M. Bliesmer

    Mr. Bliesmer, 24, has had ITDM since 2017. His endocrinologist
examined him in 2018 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. His endocrinologist certifies that Mr. Bliesmer understands
diabetes management and monitoring, has stable control of his diabetes
using insulin, and is able to drive a CMV safely. Mr. Bliesmer meets
the requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2018 and certified that he does not have
diabetic retinopathy. He holds an operator's license from Minnesota.

Theodore F. Brassley, Jr.

    Mr. Brassley, 61, has had ITDM since 2008. His endocrinologist
examined him in 2018 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. His endocrinologist certifies that Mr. Brassley understands
diabetes management and monitoring, has stable control of his diabetes
using insulin, and is able to drive a CMV safely. Mr. Brassley meets
the requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2018 and certified that

he does not have diabetic retinopathy. He holds a Class B CDL from
Maine.

Al C. Broom

    Mr. Broom, 68, has had ITDM since 2018. His endocrinologist
examined him in 2018 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. His endocrinologist certifies that Mr. Broom understands
diabetes management and monitoring, has stable control of his diabetes
using insulin, and is able to drive a CMV safely. Mr. Broom meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2018 and certified that he does not
have diabetic retinopathy. He holds an operator's license from
California.

David A. Bruns

    Mr. Bruns, 57, has had ITDM since 2017. His endocrinologist
examined him in 2018 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. His endocrinologist certifies that Mr. Bruns understands
diabetes management and monitoring, has stable control of his diabetes
using insulin, and is able to drive a CMV safely. Mr. Bruns meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2018 and certified that he has stable
proliferative diabetic retinopathy. He holds an operator's license from
Indiana.

Todd W. Burdick

    Mr. Burdick, 53, has had ITDM since 2012. His endocrinologist
examined him in 2018 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. His endocrinologist certifies that Mr. Burdick understands
diabetes management and monitoring, has stable control of his diabetes
using insulin, and is able to drive a CMV safely. Mr. Burdick meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2018 and certified that he does not have
diabetic retinopathy. He holds an operator's license from Wisconsin.

William T. Casey

    Mr. Casey, 53, has had ITDM since 2018. His endocrinologist
examined him in 2018 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. His endocrinologist certifies that Mr. Casey understands
diabetes management and monitoring, has stable control of his diabetes
using insulin, and is able to drive a CMV safely. Mr. Casey meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2018 and certified that he does not
have diabetic retinopathy. He holds a Class A CDL from Minnesota.

Anthony Castano

    Mr. Castano, 28, has had ITDM since 1997. His endocrinologist
examined him in 2018 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. His endocrinologist certifies that Mr. Castano understands
diabetes management and monitoring, has stable control of his diabetes
using insulin, and is able to drive a CMV safely. Mr. Castano meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2018 and certified that he does not have
diabetic retinopathy. He holds an operator's license from Florida.

Richard T. Cisson III

    Mr. Cisson, 21, has had ITDM since 2017. His endocrinologist
examined him in 2018 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. His endocrinologist certifies that Mr. Cisson understands
diabetes management and monitoring, has stable control of his diabetes
using insulin, and is able to drive a CMV safely. Mr. Cisson meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2018 and certified that he does not have
diabetic retinopathy. He holds an operator's license from Florida.

John F. Daley

    Mr. Daley, 59, has had ITDM since 2016. His endocrinologist
examined him in 2018 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. His endocrinologist certifies that Mr. Daley understands
diabetes management and monitoring, has stable control of his diabetes
using insulin, and is able to drive a CMV safely. Mr. Daley meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2018 and certified that he does not have
diabetic retinopathy. He holds a Class A CDL from Rhode Island.

Erik T. Davis

    Mr. Davis, 21, has had ITDM since 2009. His endocrinologist
examined him in 2018 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. His endocrinologist certifies that Mr. Davis understands
diabetes management and monitoring, has stable control of his diabetes
using insulin, and is able to drive a CMV safely. Mr. Davis meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2018 and certified that he does not have
diabetic retinopathy. He holds an operator's license from Mississippi.

Robert J. Degrave

    Mr. Degrave, 40, has had ITDM since 2017. His endocrinologist
examined him in 2018 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. His endocrinologist

certifies that Mr. Degrave understands diabetes management and
monitoring, has stable control of his diabetes using insulin, and is
able to drive a CMV safely. Mr. Degrave meets the requirements of the
vision standard at 49 CFR 391.41(b)(10). His optometrist examined him
in 2017 and certified that he does not have diabetic retinopathy. He
holds a Class A CDL from Virginia.

Paul A. Diokpa

    Mr. Diokpa, 56, has had ITDM since 2016. His endocrinologist
examined him in 2018 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. His endocrinologist certifies that Mr. Diokpa understands
diabetes management and monitoring, has stable control of his diabetes
using insulin, and is able to drive a CMV safely. Mr. Diokpa meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2018 and certified that he has stable
nonproliferative diabetic retinopathy. He holds a Class A CDL from
Illinois.

Richard E. Dodge

    Mr. Dodge, 71, has had ITDM since 2016. His endocrinologist
examined him in 2018 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. His endocrinologist certifies that Mr. Dodge understands
diabetes management and monitoring, has stable control of his diabetes
using insulin, and is able to drive a CMV safely. Mr. Dodge meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2018 and certified that he does not
have diabetic retinopathy. He holds an operator's license from Oregon.

Jeramy A. Elley

    Mr. Elley, 37, has had ITDM since 1992. His endocrinologist
examined him in 2018 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. His endocrinologist certifies that Mr. Elley understands
diabetes management and monitoring, has stable control of his diabetes
using insulin, and is able to drive a CMV safely. Mr. Elley meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2018 and certified that he does not have
diabetic retinopathy. He holds an operator's license from Montana.

John A. Evenson

    Mr. Evenson, 68, has had ITDM since 2018. His endocrinologist
examined him in 2018 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. His endocrinologist certifies that Mr. Evenson understands
diabetes management and monitoring, has stable control of his diabetes
using insulin, and is able to drive a CMV safely. Mr. Evenson meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2018 and certified that he does not have
diabetic retinopathy. He holds a Class B CDL from Minnesota.

Gregory L. Faison

    Mr. Faison, 44, has had ITDM since 2010. His endocrinologist
examined him in 2018 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. His endocrinologist certifies that Mr. Faison understands
diabetes management and monitoring, has stable control of his diabetes
using insulin, and is able to drive a CMV safely. Mr. Faison meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2018 and certified that he does not have
diabetic retinopathy. He holds an operator license from Maryland.

Ronald N. Falkowski

    Mr. Falkowski, 60, has had ITDM since 2018. His endocrinologist
examined him in 2018 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. His endocrinologist certifies that Mr. Falkowski understands
diabetes management and monitoring, has stable control of his diabetes
using insulin, and is able to drive a CMV safely. Mr. Falkowski meets
the requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2018 and certified that he does not have
diabetic retinopathy. He holds a Class A CDL from Wisconsin.

Shawn L. Floyd

    Ms. Floyd, 51, has had ITDM since 1994. Her endocrinologist
examined her in 2018 and certified that she has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. Her endocrinologist certifies that Ms. Floyd understands
diabetes management and monitoring, has stable control of her diabetes
using insulin, and is able to drive a CMV safely. Ms. Floyd meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). Her
ophthalmologist examined her in 2018 and certified that she has stable
nonproliferative diabetic retinopathy. She holds an operator's license
from Illinois.

Terrence M. Fontaine

    Mr. Fontaine, 32, has had ITDM since 1997. His endocrinologist
examined him in 2017 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. His endocrinologist certifies that Mr. Fontaine understands
diabetes management and monitoring, has stable control of his diabetes
using insulin, and is able to drive a CMV safely. Mr. Fontaine meets
the requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2018 and certified that he does not have
diabetic retinopathy. He holds an operator's license from
Massachusetts.

David G. Foster

    Mr. Foster, 59, has had ITDM since 2010. His endocrinologist
examined him in 2018 and certified that he has had no

severe hypoglycemic reactions resulting in loss of consciousness,
requiring the assistance of another person, or resulting in impaired
cognitive function that occurred without warning in the past 12 months
and no recurrent (two or more) severe hypoglycemic episodes in the last
five years. His endocrinologist certifies that Mr. Foster understands
diabetes management and monitoring, has stable control of his diabetes
using insulin, and is able to drive a CMV safely. Mr. Foster meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2018 and certified that he does not
have diabetic retinopathy. He holds an operator's license from
Michigan.

Daniel A. Fry

    Mr. Fry, 66, has had ITDM since 2018. His endocrinologist examined
him in 2018 and certified that he has had no severe hypoglycemic
reactions resulting in loss of consciousness, requiring the assistance
of another person, or resulting in impaired cognitive function that
occurred without warning in the past 12 months and no recurrent (two or
more) severe hypoglycemic episodes in the last five years. His
endocrinologist certifies that Mr. Fry understands diabetes management
and monitoring, has stable control of his diabetes using insulin, and
is able to drive a CMV safely. Mr. Fry meets the requirements of the
vision standard at 49 CFR 391.41(b)(10). His optometrist examined him
in 2018 and certified that he does not have diabetic retinopathy. He
holds a Class A CDL from Pennsylvania.

Samuel L. Gillespie

    Mr. Gillespie, 53, has had ITDM since 2016. His endocrinologist
examined him in 2017 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. His endocrinologist certifies that Mr. Gillespie understands
diabetes management and monitoring, has stable control of his diabetes
using insulin, and is able to drive a CMV safely. Mr. Gillespie meets
the requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2018 and certified that he has stable
nonproliferative diabetic retinopathy. He holds a Class AM CDL from
Tennessee.

Eddie C. Hall

    Mr. Hall, 57, has had ITDM since 2011. His endocrinologist examined
him in 2018 and certified that he has had no severe hypoglycemic
reactions resulting in loss of consciousness, requiring the assistance
of another person, or resulting in impaired cognitive function that
occurred without warning in the past 12 months and no recurrent (two or
more) severe hypoglycemic episodes in the last five years. His
endocrinologist certifies that Mr. Hall understands diabetes management
and monitoring, has stable control of his diabetes using insulin, and
is able to drive a CMV safely. Mr. Hall meets the requirements of the
vision standard at 49 CFR 391.41(b)(10). His ophthalmologist examined
him in 2018 and certified that he does not have diabetic retinopathy.
He holds a Class A CDL from Florida.

Jacob E. Heubner

    Mr. Heubner, 40, has had ITDM since 2017. His endocrinologist
examined him in 2018 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. His endocrinologist certifies that Mr. Heubner understands
diabetes management and monitoring, has stable control of his diabetes
using insulin, and is able to drive a CMV safely. Mr. Heubner meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2017 and certified that he does not have
diabetic retinopathy. He holds a Class A CDL from Indiana.

Michael P. Johnson

    Mr. Johnson, 54, has had ITDM since 2015. His endocrinologist
examined him in 2018 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. His endocrinologist certifies that Mr. Johnson understands
diabetes management and monitoring, has stable control of his diabetes
using insulin, and is able to drive a CMV safely. Mr. Johnson meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2018 and certified that he has stable
nonproliferative diabetic retinopathy. He holds a Class A CDL from
Minnesota.

Ryan J. Keys

    Mr. Keys, 21, has had ITDM since 1998. His endocrinologist examined
him in 2018 and certified that he has had no severe hypoglycemic
reactions resulting in loss of consciousness, requiring the assistance
of another person, or resulting in impaired cognitive function that
occurred without warning in the past 12 months and no recurrent (two or
more) severe hypoglycemic episodes in the last five years. His
endocrinologist certifies that Mr. Keys understands diabetes management
and monitoring, has stable control of his diabetes using insulin, and
is able to drive a CMV safely. Mr. Keys meets the requirements of the
vision standard at 49 CFR 391.41(b)(10). His ophthalmologist examined
him in 2018 and certified that he does not have diabetic retinopathy.
He holds an operator from New York.

James C. Lee, Jr.

    Mr. Lee, 40, has had ITDM since 2013. His endocrinologist examined
him in 2018 and certified that he has had no severe hypoglycemic
reactions resulting in loss of consciousness, requiring the assistance
of another person, or resulting in impaired cognitive function that
occurred without warning in the past 12 months and no recurrent (two or
more) severe hypoglycemic episodes in the last five years. His
endocrinologist certifies that Mr. Lee understands diabetes management
and monitoring, has stable control of his diabetes using insulin, and
is able to drive a CMV safely. Mr. Lee meets the requirements of the
vision standard at 49 CFR 391.41(b)(10). His ophthalmologist examined
him in 2018 and certified that he has stable nonproliferative diabetic
retinopathy. He holds an operator's license from Georgia.

Harold W. Lewis, Jr.

    Mr. Lewis, 58, has had ITDM since 2010. His endocrinologist
examined him in 2018 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. His endocrinologist certifies that Mr. Lewis understands
diabetes management and monitoring, has stable control of his diabetes
using insulin, and is able to drive a CMV safely. Mr. Lewis meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist

examined him in 2018 and certified that he does not have diabetic
retinopathy. He holds an operator's license from Maryland.

Edward T. Martin

    Mr. Martin, 71, has had ITDM since 2015. His endocrinologist
examined him in 2017 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. His endocrinologist certifies that Mr. Martin understands
diabetes management and monitoring, has stable control of his diabetes
using insulin, and is able to drive a CMV safely. Mr. Martin meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2018 and certified that he does not
have diabetic retinopathy. He holds a Class A CDL from Minnesota.

Clavenda L. Mason

    Ms. Mason, 64, has had ITDM since 2015. Her endocrinologist
examined her in 2017 and certified that she has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. Her endocrinologist certifies that Ms. Mason understands
diabetes management and monitoring, has stable control of her diabetes
using insulin, and is able to drive a CMV safely. Ms. Mason meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). Her
ophthalmologist examined her in 2018 and certified that she has stable
nonproliferative diabetic retinopathy. She holds an operator's license
from Maryland.

Derek A. McGinty

    Mr. McGinty, 45, has had ITDM since 2018. His endocrinologist
examined him in 2018 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. His endocrinologist certifies that Mr. McGinty understands
diabetes management and monitoring, has stable control of his diabetes
using insulin, and is able to drive a CMV safely. Mr. McGinty meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2018 and certified that he does not have
diabetic retinopathy. He holds a Class A CDL from Wisconsin.

Pamela J. Meziere

    Ms. Meziere, 53, has had ITDM since 1973. Her endocrinologist
examined her in 2018 and certified that she has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. Her endocrinologist certifies that Ms. Meziere understands
diabetes management and monitoring, has stable control of her diabetes
using insulin, and is able to drive a CMV safely. Ms. Meziere meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). Her
optometrist examined her in 2018 and certified that she does not have
diabetic retinopathy. She holds a Class A CDL from Mississippi.

Mark A. Miller

    Mr. Miller, 36, has had ITDM since 1993. His endocrinologist
examined him in 2018 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. His endocrinologist certifies that Mr. Miller understands
diabetes management and monitoring, has stable control of his diabetes
using insulin, and is able to drive a CMV safely. Mr. Miller meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2018 and certified that he does not have
diabetic retinopathy. He holds an operator's license from Indiana.

Donald R. Mocaby

    Mr. Mocaby, 72, has had ITDM since 2017. His endocrinologist
examined him in 2018 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. His endocrinologist certifies that Mr. Mocaby understands
diabetes management and monitoring, has stable control of his diabetes
using insulin, and is able to drive a CMV safely. Mr. Mocaby meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2018 and certified that he does not have
diabetic retinopathy. He holds an operator's license from Illinois.

David B. Morel

    Mr. Morel, 62, has had ITDM since 2017. His endocrinologist
examined him in 2018 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. His endocrinologist certifies that Mr. Morel understands
diabetes management and monitoring, has stable control of his diabetes
using insulin, and is able to drive a CMV safely. Mr. Morel meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2017 and certified that he has stable
nonproliferative diabetic retinopathy. He holds an operator's license
from New Hampshire.

Cornelius W. Ott, Jr.

    Mr. Ott, 63, has had ITDM since 2016. His endocrinologist examined
him in 2018 and certified that he has had no severe hypoglycemic
reactions resulting in loss of consciousness, requiring the assistance
of another person, or resulting in impaired cognitive function that
occurred without warning in the past 12 months and no recurrent (two or
more) severe hypoglycemic episodes in the last five years. His
endocrinologist certifies that Mr. Ott understands diabetes management
and monitoring, has stable control of his diabetes using insulin, and
is able to drive a CMV safely. Mr. Ott meets the requirements of the
vision standard at 49 CFR 391.41(b)(10). His ophthalmologist examined
him in 2018 and certified that he does not have diabetic retinopathy.
He holds an operator's license from Illinois.

Gene H. Owens

    Mr. Owens, 68, has had ITDM since 2005. His endocrinologist
examined him in 2018 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function

that occurred without warning in the past 12 months and no recurrent
(two or more) severe hypoglycemic episodes in the last five years. His
endocrinologist certifies that Mr. Owens understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Owens meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2018 and certified that he has stable
nonproliferative diabetic retinopathy. He holds a Class A CDL from
Kansas.

Jarek D. Perkins

    Mr. Perkins, 32, has had ITDM since 1991. His endocrinologist
examined him in 2018 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. His endocrinologist certifies that Mr. Perkins understands
diabetes management and monitoring, has stable control of his diabetes
using insulin, and is able to drive a CMV safely. Mr. Perkins meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2018 and certified that he has stable
nonproliferative diabetic retinopathy. He holds an operator's license
from Ohio.

Austin S. Pihuliak

    Mr. Pihuliak, 22, has had ITDM since 2017. His endocrinologist
examined him in 2018 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. His endocrinologist certifies that Mr. Pihuliak understands
diabetes management and monitoring, has stable control of his diabetes
using insulin, and is able to drive a CMV safely. Mr. Pihuliak meets
the requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2018 and certified that he does not have
diabetic retinopathy. He holds a Class A CDL from Ohio.

Michael P. Poisson

    Mr. Poisson, 41, has had ITDM since 2014. His endocrinologist
examined him in 2018 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. His endocrinologist certifies that Mr. Poisson understands
diabetes management and monitoring, has stable control of his diabetes
using insulin, and is able to drive a CMV safely. Mr. Poisson meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2018 and certified that he does not
have diabetic retinopathy. He holds an operator's license from
Michigan.

Carl E. Rhoads

    Mr. Rhoads, 67, has had ITDM since 2013. His endocrinologist
examined him in 2018 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. His endocrinologist certifies that Mr. Rhoads understands
diabetes management and monitoring, has stable control of his diabetes
using insulin, and is able to drive a CMV safely. Mr. Rhoads meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2018 and certified that he does not have
diabetic retinopathy. He holds a Class A CDL from Illinois.

John W. Ringbloom

    Mr. Ringbloom, 66, has had ITDM since 2016. His endocrinologist
examined him in 2018 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. His endocrinologist certifies that Mr. Ringbloom understands
diabetes management and monitoring, has stable control of his diabetes
using insulin, and is able to drive a CMV safely. Mr. Ringbloom meets
the requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2018 and certified that he does not have
diabetic retinopathy. He holds an operator's license from Pennsylvania.

Leslie M. Rinker

    Mr. Rinker, 70, has had ITDM since 2009. His endocrinologist
examined him in 2018 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. His endocrinologist certifies that Mr. Rinker understands
diabetes management and monitoring, has stable control of his diabetes
using insulin, and is able to drive a CMV safely. Mr. Rinker meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2018 and certified that he does not
have diabetic retinopathy. He holds a Class A CDL from Virginia.

Rocky G. Roof

    Mr. Roof, 51, has had ITDM since 2017. His endocrinologist examined
him in 2018 and certified that he has had no severe hypoglycemic
reactions resulting in loss of consciousness, requiring the assistance
of another person, or resulting in impaired cognitive function that
occurred without warning in the past 12 months and no recurrent (two or
more) severe hypoglycemic episodes in the last five years. His
endocrinologist certifies that Mr. Roof understands diabetes management
and monitoring, has stable control of his diabetes using insulin, and
is able to drive a CMV safely. Mr. Roof meets the requirements of the
vision standard at 49 CFR 391.41(b)(10). His ophthalmologist examined
him in 2017 and certified that he does not have diabetic retinopathy.
He holds an operator's license from Missouri.

Lance U. Sapp

    Mr. Sapp, 68, has had ITDM since 2017. His endocrinologist examined
him in 2018 and certified that he has had no severe hypoglycemic
reactions resulting in loss of consciousness, requiring the assistance
of another person, or resulting in impaired cognitive function that
occurred without warning in the past 12 months and no recurrent (two or
more) severe hypoglycemic episodes in the last five years. His
endocrinologist certifies that Mr. Sapp understands diabetes management
and monitoring, has stable control of his diabetes using insulin, and
is able to drive a CMV safely. Mr. Sapp meets the requirements of the
vision standard at 49 CFR 391.41(b)(10). His optometrist examined him
in 2018 and certified that he does

not have diabetic retinopathy. He holds a Class A CDL from North
Dakota.

Dwayne E. Smith

    Mr. Smith, 55, has had ITDM since 2017. His endocrinologist
examined him in 2018 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. His endocrinologist certifies that Mr. Smith understands
diabetes management and monitoring, has stable control of his diabetes
using insulin, and is able to drive a CMV safely. Mr. Smith meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2018 and certified that he does not
have diabetic retinopathy. He holds a Class B CDL from New York.

Brian C. Smith

    Mr. Smith, 39, has had ITDM since 1988. His endocrinologist
examined him in 2018 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. His endocrinologist certifies that Mr. Smith understands
diabetes management and monitoring, has stable control of his diabetes
using insulin, and is able to drive a CMV safely. Mr. Smith meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2018 and certified that he has stable
nonproliferative diabetic retinopathy. He holds an operator's license
from California.

Alex L. Soto

    Mr. Soto, 27, has had ITDM since 2017. His endocrinologist examined
him in 2018 and certified that he has had no severe hypoglycemic
reactions resulting in loss of consciousness, requiring the assistance
of another person, or resulting in impaired cognitive function that
occurred without warning in the past 12 months and no recurrent (two or
more) severe hypoglycemic episodes in the last five years. His
endocrinologist certifies that Mr. Soto understands diabetes management
and monitoring, has stable control of his diabetes using insulin, and
is able to drive a CMV safely. Mr. Soto meets the requirements of the
vision standard at 49 CFR 391.41(b)(10). His optometrist examined him
in 2018 and certified that he does not have diabetic retinopathy. He
holds a Class A CDL from California.

Scott K. Stauffer

    Mr. Stauffer, 59, has had ITDM since 2009. His endocrinologist
examined him in 2018 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. His endocrinologist certifies that Mr. Stauffer understands
diabetes management and monitoring, has stable control of his diabetes
using insulin, and is able to drive a CMV safely. Mr. Stauffer meets
the requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2018 and certified that he does not have
diabetic retinopathy. He holds an operator's license from Pennsylvania.

Jerry F. Summers

    Mr. Summers, 38, has had ITDM since 2013. His endocrinologist
examined him in 2018 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. His endocrinologist certifies that Mr. Summers understands
diabetes management and monitoring, has stable control of his diabetes
using insulin, and is able to drive a CMV safely. Mr. Summers meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2018 and certified that he does not have
diabetic retinopathy. He holds an operator's license from New
Hampshire.

Gary R. Waldvogel

    Mr. Waldvogel, 58, has had ITDM since 2018. His endocrinologist
examined him in 2018 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. His endocrinologist certifies that Mr. Waldvogel understands
diabetes management and monitoring, has stable control of his diabetes
using insulin, and is able to drive a CMV safely. Mr. Waldvogel meets
the requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2018 and certified that he does not have
diabetic retinopathy. He holds a Class A CDL from Minnesota.

Lee H. Watkins

    Mr. Watkins, 77, has had ITDM since 2017. His endocrinologist
examined him in 2018 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. His endocrinologist certifies that Mr. Watkins understands
diabetes management and monitoring, has stable control of his diabetes
using insulin, and is able to drive a CMV safely. Mr. Watkins meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2018 and certified that he does not
have diabetic retinopathy. He holds a Class A CDL from Ohio.

John D. Wenger, Jr.

    Mr. Wenger, 66, has had ITDM since 1998. His endocrinologist
examined him in 2018 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. His endocrinologist certifies that Mr. Wenger understands
diabetes management and monitoring, has stable control of his diabetes
using insulin, and is able to drive a CMV safely. Mr. Wenger meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2018 and certified that he does not have
diabetic retinopathy. He holds an operator's license from Missouri.

David B. Whitehead

    Mr. Whitehead, 44, has had ITDM since 2017. His endocrinologist
examined him in 2018 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more)

severe hypoglycemic episodes in the last five years. His
endocrinologist certifies that Mr. Whitehead understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Whitehead meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2018 and certified that he does not have
diabetic retinopathy. He holds a Class A CDL from North Carolina.

John J. Wille III

    Mr. Wille, 60, has had ITDM since 2017. His endocrinologist
examined him in 2018 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. His endocrinologist certifies that Mr. Wille understands
diabetes management and monitoring, has stable control of his diabetes
using insulin, and is able to drive a CMV safely. Mr. Wille meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2018 and certified that he does not have
diabetic retinopathy. He holds an operator's license from Utah.

Douglas W. Winslow

    Mr. Winslow, 53, has had ITDM since 1991. His endocrinologist
examined him in 2018 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. His endocrinologist certifies that Mr. Winslow understands
diabetes management and monitoring, has stable control of his diabetes
using insulin, and is able to drive a CMV safely. Mr. Winslow meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2018 and certified that he has stable
nonproliferative diabetic retinopathy. He holds an operator's license
from Illinois.

Christopher S. Wright

    Mr. Wright, 53, has had ITDM since 2018. His endocrinologist
examined him in 2018 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (two or more) severe hypoglycemic episodes in the last five
years. His endocrinologist certifies that Mr. Wright understands
diabetes management and monitoring, has stable control of his diabetes
using insulin, and is able to drive a CMV safely. Mr. Wright meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2018 and certified that he does not have
diabetic retinopathy. He holds a Class A CDL from Illinois.

III. Request for Comments

    In accordance with 49 U.S.C. 31136(e) and 31315, FMCSA requests
public comment from all interested persons on the exemption petitions
described in this notice. We will consider all comments received before
the close of business on the closing date indicated in the dates
section of the notice.

IV. Submitting Comments

    You may submit your comments and material online or by fax, mail,
or hand delivery, but please use only one of these means. FMCSA
recommends that you include your name and a mailing address, an email
address, or a phone number in the body of your document so that FMCSA
can contact you if there are questions regarding your submission.
    To submit your comment online, go to http://www.regulations.gov and
in the search box insert the docket number FMCSA-2018-0033 and click
the search button. When the new screen appears, click on the blue
``Comment Now!'' button on the right hand side of the page. On the new
page, enter information required including the specific section of this
document to which each comment applies, and provide a reason for each
suggestion or recommendation. If you submit your comments by mail or
hand delivery, submit them in an unbound format, no larger than 8\1/2\
by 11 inches, suitable for copying and electronic filing. If you submit
comments by mail and would like to know that they reached the facility,
please enclose a stamped, self-addressed postcard or envelope.
    We will consider all comments and materials received during the
comment period. FMCSA may issue a final determination at any time after
the close of the comment period.

V. Viewing Comments and Documents

    To view comments, as well as any documents mentioned in this
preamble, go to http://www.regulations.gov and in the search box insert
the docket number FMCSA-2018-0033 and click ``Search.'' Next, click
``Open Docket Folder'' and you will find all documents and comments
related to this notice.

    Issued on: July 13, 2018.
Larry W. Minor,
Associate Administrator for Policy.
[FR Doc. 2018-15542 Filed 7-19-18; 8:45 am]
 BILLING CODE 4910-EX-P


[Federal Register Volume 80, Number 209 (Thursday, October 29, 2015)]
[Notices]
[Page 66609]
[FR Doc No: 2015-27521]

-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-76254; File No. SR-CBOE-2015-045]

Self-Regulatory Organizations; Chicago Board Options Exchange,
Incorporated; Notice of Withdrawal of Proposed Rule Change, as Modified
by Amendment No. 1, Relating to Rule 6.53C and Complex Orders on the
Hybrid System

October 23, 2015.
    On May 12, 2015, the Chicago Board Options Exchange, Incorporated
(``CBOE'') filed with the Securities and Exchange Commission
(``Commission''), pursuant to Section 19(b)(1) of the Securities
Exchange Act of 1934 \1\ and Rule 19b-4 thereunder,\2\ a proposed rule
change to modify CBOE Rule 6.53C, Complex Orders on the Hybrid System,
regarding eligibility for participation in the Complex Order Book and
the Complex Order Auction (``COA''). The proposed rule change was
published for comment in the Federal Register on May 27, 2015.\3\ On
June 3, 2015, CBOE filed Amendment No.1 to the proposed rule change.\4\
On July 6, 2015, the Commission extended the time period within which
to approve the proposed rule change, disapprove the proposed rule
change, or institute proceedings to determine whether to disapprove the
proposed rule change, to August 25, 2015.\5\ On August 19, 2015, the
Commission instituted proceedings to determine whether to approve or
disapprove the proposed rule change, as modified by Amendment No. 1.\6\
The Commission received no comments on the proposed rule change, as
modified by Amendment No. 1. On September 8, 2015, CBOE withdrew the
proposed rule change (SR-CBOE-2015-045).
---------------------------------------------------------------------------

    \1\ 15 U.S.C. 78s(b)(1).
    \2\ 17 CFR 240.19b-4.
    \3\ See Securities Exchange Act Release No. 75003 (May 20,
2015), 80 FR 30306.
    \4\ Amendment No. 1 to the proposed rule change amended the
statutory basis and burden on competition sections regarding
distinguishing between Professional and non-Professional orders for
purposes of determining eligibility for COA.
    \5\ See Securities Exchange Act Release No. 75359 (July 6,
2015), 80 FR 39821.
    \6\ See Securities Exchange Act Release No. 75736 (August 19,
2015), 80 FR 51642.
    \7\ 17 CFR 200.30-3(a)(12).

    For the Commission, by the Division of Trading and Markets,
pursuant to delegated authority.\7\
Robert W. Errett
Deputy Secretary.
[FR Doc. 2015-27521 Filed 10-28-15; 8:45 am]
 BILLING CODE 8011-01-P